Genocea Biosciences Statistics
Share Statistics
Genocea Biosciences has 0
shares outstanding. The number of shares has increased by 7.99%
in one year.
| Shares Outstanding | n/a |
| Shares Change (YoY) | 7.99% |
| Shares Change (QoQ) | 2.33% |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | n/a |
| FTD / Avg. Volume | n/a |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -5.16 and the forward
PE ratio is null.
Genocea Biosciences's PEG ratio is
0.07.
| PE Ratio | -5.16 |
| Forward PE | n/a |
| PS Ratio | 48.47 |
| Forward PS | n/a |
| PB Ratio | 2.94 |
| P/FCF Ratio | -1.63 |
| PEG Ratio | 0.07 |
Financial Ratio HistoryEnterprise Valuation
Genocea Biosciences has an Enterprise Value (EV) of 53.53M.
| EV / Sales | 32.62 |
| EV / EBITDA | -1.56 |
| EV / EBIT | -1.18 |
| EV / FCF | -1.1 |
Financial Position
The company has a current ratio of 2.24,
with a Debt / Equity ratio of 0.41.
| Current Ratio | 2.24 |
| Quick Ratio | 2.24 |
| Debt / Equity | 0.41 |
| Debt / EBITDA | -0.32 |
| Debt / FCF | -0.23 |
| Interest Coverage | 46.47 |
Financial Efficiency
Return on Equity is -56.95% and Return on Invested Capital is -63.33%.
| Return on Equity | -56.95% |
| Return on Assets | -27.55% |
| Return on Invested Capital | -63.33% |
| Revenue Per Employee | $22,175.68 |
| Profits Per Employee | $-208,378.38 |
| Employee Count | 74 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -17.78M |
| Effective Tax Rate | 53.55% |
Stock Price Statistics
The stock price has increased by null% in the
last 52 weeks. The beta is 0, so Genocea Biosciences's
price volatility has been lower than the market average.
| Beta | 0 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 0.01 |
| 200-Day Moving Average | 0.22 |
| Relative Strength Index (RSI) | 41.09 |
| Average Volume (20 Days) | 80,568 |
Income Statement
In the last 12 months, Genocea Biosciences had revenue of 1.64M
and earned -15.42M
in profits. Earnings per share was -0.22.
| Revenue | 1.64M |
| Gross Profit | 1.64M |
| Operating Income | -52.09M |
| Net Income | -15.42M |
| EBITDA | -34.32M |
| EBIT | -34.32M |
| Earnings Per Share (EPS) | -0.22 |
Full Income StatementBalance Sheet
The company has 37.15M in cash and 11.13M in
debt, giving a net cash position of 26.02M.
| Cash & Cash Equivalents | 37.15M |
| Total Debt | 11.13M |
| Net Cash | 26.02M |
| Retained Earnings | -407.86M |
| Total Assets | n/a |
| Working Capital | n/a |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -45.37M
and capital expenditures -3.29M, giving a free cash flow of -48.66M.
| Operating Cash Flow | -45.37M |
| Capital Expenditures | -3.29M |
| Free Cash Flow | -48.66M |
| FCF Per Share | -0.71 |
Full Cash Flow StatementMargins
Gross margin is 100%, with operating and profit margins of -3174.47% and -939.67%.
| Gross Margin | 100% |
| Operating Margin | -3174.47% |
| Pretax Margin | -2022.91% |
| Profit Margin | -939.67% |
| EBITDA Margin | -2091.22% |
| EBIT Margin | -3174.47% |
| FCF Margin | -2965.14% |
